EFTR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.70%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

eFFECTOR Therapeutics Insider Trading History Chart

eFFECTOR Therapeutics Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 04/2/2025 01:00 AM ET

Days: 30 | 90 | 365

eFFECTOR Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/27/2023	Sr One Capital Management, Llc	Major Shareholder	Sell	24,366	$15.25	$371,581.50	72,856
10/4/2022	Christopher B. Ehrlich	Director	Buy	13	$14.25	$185.25	1,408
9/26/2022	Christopher B. Ehrlich	Director	Buy	754	$13.75	$10,367.50	1,394
8/3/2022	Presidio Management Group X Ll	Major Shareholder	Sell	2,375	$20.00	$47,500.00	5,102
8/1/2022	Presidio Management Group X Ll	Major Shareholder	Sell	1,068	$19.75	$21,093.00	5,208
7/27/2022	Presidio Management Group X Ll	Major Shareholder	Sell	1,746	$22.25	$38,848.50	5,280
7/25/2022	Presidio Management Group X Ll	Major Shareholder	Sell	91	$23.25	$2,115.75	5,336
7/22/2022	Presidio Management Group X Ll	Major Shareholder	Sell	304	$22.75	$6,916.00	5,339
7/20/2022	Presidio Management Group X Ll	Major Shareholder	Sell	401	$25.00	$10,025.00	5,351
7/18/2022	Presidio Management Group X Ll	Major Shareholder	Sell	839	$27.00	$22,653.00	5,367
7/15/2022	Presidio Management Group X Ll	Major Shareholder	Sell	1,836	$27.75	$50,949.00	5,392
6/23/2022	Brian M Jr. Gallagher	Director	Buy	1,200	$39.75	$47,700.00	1,200
6/7/2022	Michael Byrnes	CFO	Buy	1,000	$33.25	$33,250.00	1,169
6/7/2022	Stephen T Worland	Insider	Buy	800	$34.25	$27,400.00	8,599
5/18/2022	Presidio Management Group X Ll	Major Shareholder	Sell	563	$43.25	$24,349.75	5,460
5/16/2022	Presidio Management Group X Ll	Major Shareholder	Sell	510	$43.75	$22,312.50	5,492
5/13/2022	Presidio Management Group X Ll	Major Shareholder	Sell	904	$46.00	$41,584.00	5,508
5/11/2022	Presidio Management Group X Ll	Major Shareholder	Sell	200	$58.75	$11,750.00	5,549
5/9/2022	Presidio Management Group X Ll	Major Shareholder	Sell	160	$63.50	$10,160.00	5,605

See Full Table

SEC Filings (Institutional Ownership Changes) for eFFECTOR Therapeutics (NASDAQ:EFTR)

57.67% of eFFECTOR Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

eFFECTOR Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/16/2024	Blackstone Inc.	52,343	$0.75M	0.0%	-96.0%	1.419%
5/14/2024	StemPoint Capital LP	132,793	$1.91M	0.5%	N/A	3.599%
5/3/2024	Carlyle Group Inc.	192,884	$2.72M	0.2%	-96.0%	5.227%
11/13/2023	Column Group LLC	4,026,224	$2.42M	1.6%	-6.6%	9.496%
11/2/2023	Sonora Investment Management Group LLC	125,000	$75K	0.0%	N/A	0.295%
6/5/2023	EP Wealth Advisors LLC	17,607	$1.65M	0.0%	N/A	0.042%
5/5/2023	Carlyle Group Inc.	4,822,114	$1.69M	0.1%	N/A	11.373%
8/16/2022	Callan Capital LLC	20,000	$28K	0.0%	N/A	0.048%
8/2/2022	Resolute Financial LLC	30,000	$43K	0.0%	N/A	0.072%
8/1/2022	Parallel Advisors LLC	1,693,559	$2.41M	0.1%	+150.0%	4.092%
4/28/2022	Parallel Advisors LLC	677,452	$2.74M	0.1%	N/A	1.637%
2/15/2022	SR One Capital Management LP	6,822,114	$56.49M	31.9%	N/A	16.898%
2/9/2022	Alps Advisors Inc.	51,942	$0.43M	0.0%	N/A	0.129%
2/3/2022	OUP Management Co. LLC	1,025,697	$8.49M	3.8%	N/A	2.541%
11/16/2021	Verition Fund Management LLC	24,667	$0.35M	0.0%	N/A	0.061%
11/15/2021	Abingworth LLP	4,822,114	$67.03M	15.2%	N/A	11.964%
11/15/2021	Sectoral Asset Management Inc	2,882,744	$40.50M	3.4%	N/A	7.153%

Data available starting January 2016

See Full Table

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Today's Range

Now: $0.00

$0.00

50 Day Range

MA: N/A

52 Week Range

Now: $0.00

$0.00

$16.88

Volume

33 shs

Average Volume

2,052 shs

Market Capitalization

$940.80

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54

Who are the company insiders with the largest holdings of eFFECTOR Therapeutics?: eFFECTOR Therapeutics' top insider investors include:
Sr One Capital Management, Llc (Major Shareholder)
Learn More about top insider investors at eFFECTOR Therapeutics.